Mostrar el registro sencillo del ítem

dc.contributorUniversitat de Vic - Universitat Central de Catalunya. Facultat de Medicina
dc.contributorInstitut d’Investigacions Biomèdiques de Barcelona (IIBB-CSIC)
dc.contributorCentro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
dc.contributorUniversitat de Barcelona
dc.contributorInstituto de Investigaciones Biológicas Clemente Estable
dc.contributorCentro de Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)
dc.contributorInstitut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
dc.contributor.authorTarrés-Gatius, Mireia
dc.contributor.authorLópez Hill, Ximena
dc.contributor.authorMiquel-Rio, Lluís
dc.contributor.authorCastarlenas, Laura
dc.contributor.authorFabius, Sara
dc.contributor.authorSantana, Noemí
dc.contributor.authorVilaró, M. Teresa
dc.contributor.authorArtigas, Francesc
dc.contributor.authorScorza, María Cecilia
dc.contributor.authorCastañé Forn, Anna
dc.date.accessioned2025-07-02T13:28:27Z
dc.date.available2025-07-02T13:28:27Z
dc.date.created2025-07
dc.date.issued2022
dc.identifier.citationarrés-Gatius, M., López-Hill, X., Miquel-Rio, L., Castarlenas, L., Fabius, S., Santana, N., Vilaró, M. T., Artigas, F., Scorza, M. C., & Castañé, A. (2022). Discrimination of motor and sensorimotor effects of phencyclidine and MK-801: Involvement of GluN2C-containing NMDA receptors in psychosis-like models. Neuropharmacology, 213, 109079. https://doi.org/10.1016/j.neuropharm.2022.109079ca
dc.identifier.issn1873-7064ca
dc.identifier.urihttp://hdl.handle.net/10854/180278
dc.description.abstractNon-competitive NMDA receptor (NMDA-R) antagonists like ketamine, phencyclidine (PCP) and MK-801 are routinely used as pharmacological models of schizophrenia. However, the NMDA-R subtypes, neuronal types (e.g., GABA vs. glutamatergic neurons) and brain regions involved in psychotomimetic actions are not fully understood. PCP activates thalamo-cortical circuits after NMDA-R blockade in reticular thalamic GABAergic neurons. GluN2C subunits are densely expressed in thalamus and cerebellum. Therefore, we examined their involvement in the behavioral and functional effects elicited by PCP and MK-801 using GluN2C knockout (GluN2CKO) and wild-type mice, under the working hypothesis that psychotomimetic effects should be attenuated in mutant mice. PCP and MK-801 induced a disorganized and meandered hyperlocomotion in both genotypes. Interestingly, stereotyped behaviors like circling/rotation, rearings and ataxia signs were dramatically reduced in GluN2CKO mice, indicating a better motor coordination in absence of GluN2C subunits. In contrast, other motor or sensorimotor (pre-pulse inhibition of the startle response) aspects of the behavioral syndrome remained unaltered by GluN2C deletion. PCP and MK-801 evoked a general pattern of c-fos activation in mouse brain (including thalamo-cortical networks) but not in the cerebellum, where they markedly reduced c-fos expression, with significant genotype differences paralleling those in motor coordination. Finally, resting-state fMRI showed an enhanced cortico-thalamic-cerebellar connectivity in GluN2CKO mice, less affected by MK-801 than controls. Hence, the GluN2C subunit allows the dissection of the behavioral alterations induced by PCP and MK-801, showing that some motor effects (in particular, motor incoordination), but not deficits in sensorimotor gating, likely depend on GluN2C-containing NMDA-R blockade in cerebellar circuits.ca
dc.format.extent48 p.ca
dc.language.isoengca
dc.publisherPergamon Pressca
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.otherCervellca
dc.subject.otherCerebelca
dc.subject.otherEsquizofrèniaca
dc.subject.otherTàlemca
dc.titleDiscrimination of motor and sensorimotor effects of phencyclidine and MK-801: Involvement of GluN2C-containing NMDA receptors in psychosis-like modelsca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/acceptedVersionca
dc.embargo.termscapca
dc.identifier.doihttps://doi.org/10.1016/j.neuropharm.2022.109079ca
dc.rights.accessLevelinfo:eu-repo/semantics/openAccess
dc.subject.udc61ca


Ficheros en el ítem

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como http://creativecommons.org/licenses/by-nc-nd/4.0/
Compartir en TwitterCompartir en LinkedinCompartir en FacebookCompartir en TelegramCompartir en WhatsappImprimir